By
WilD on
September 10, 2012
What would you say if someone offered you a safe pill that could lower your blood sugar, help you lose weight, preserve beta cell function, and keep Alzheimer’s at bay?
Actually, that’s the wrong question. The question isn’t what you would say, but what would you pay?
That’s likely the question that was on the boardroom table at bio-tech firm Metabolic Solutions Development Company (MSDC), when they bet the $55-million farm on their pair of…
Read more »
Results of the seven-year-long TODAY study (Treatment Options for Type 2 Diabetes in Adolescents and Youth) are out and as expected, they aren’t pretty.
Bottom line of this study, which is the largest of its kind to ever be done: No matter what medication’s being used, kids and teens have a harder time managing their type 2 diabetes and keeping blood sugars down. Lifestyle interventions and medications aren’t working even when they’re taken as prescribed,…
Read more »
The biggest thing in diabetes headlines of late is Bydureon, the first and only once-a-week drug to help type 2 diabetics keep their sugars in check, which is newly approved by the FDA. Amylin’s stock price is up, and the pharma blogosphere is all abuzz. But if you’re like us, you may be wondering what the really big deal is. New type 2 drugs come out all the time, don’t they?
Well, for one thing,…
Read more »
A week ago, the media was all abuzz about a new study published in the New England Journal of Medicine showing that the oral drug Actos can prevent diabetes. At first we at the ‘Mine didn’t pay much attention, because of course we’re more concerned with what happens to people who already have diabetes. But the buzz didn’t stop. Forbes blogger Matthew Herper wrote a great piece about why side effects make this a bad…
Read more »
Get ready for a slew of diabetes news announcements, because the ADA’s huge annual conference starts today!
I’ll be on an airplane pretty much all day (Friday) heading out to Orlando to cover this conference live, although I must warn you: it’s quite overwhelming. Running around the 450,000 square-foot convention center trying to see every diabetes company represented in the enormous exhibit halls while hundreds of symposia and other talk sessions are happening simultaneously is…
Read more »
